Shots:
- Bayer & Suzhou Puhe BioPharma have entered into a global license agreement for Puhe BioPharma’s PRMT5 inhibitor to treat MTAP-deleted tumors
- As per the deal, Bayer will obtain rights to develop, manufacture & commercialize MTA-cooperative PRMT5 inhibitor globally; financial terms remain undisclosed
- Bayer to develop the asset under development name BAY 3713372, with first pts enrollment reported in P-I dose escalation study for the treatment of MTAP-deleted solid tumors
Ref: Bayer | Image: Bayer & Suzhou Puhe BioPharma
Related News:- Bayer Reports the US FDA’s sNDA Acceptance & Priority Review of Finerenone for Heart Failure (HF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
